<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297515</url>
  </required_header>
  <id_info>
    <org_study_id>TG2017</org_study_id>
    <nct_id>NCT03297515</nct_id>
  </id_info>
  <brief_title>Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease</brief_title>
  <acronym>MADEOS</acronym>
  <official_title>Prospective, Randomised, Double-blind Study to Assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthalmos Research and Education Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ophthalmos Research and Education Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomised, double-blind study to assess the Therapeutic Potential of Omega-3&#xD;
      Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular&#xD;
      Degeneration Omega-3 Study - MADEOS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Age-related macular degeneration (AMD) is the leading cause of blindness in developed&#xD;
      countries. By the year 2040, the number of people suffering from AMD is estimated to increase&#xD;
      by 50%. Stargardt disease is the most prevalent form of macular dystrophy in children, with&#xD;
      an estimated prevalence of 1 in 10000.&#xD;
&#xD;
      There is no effective treatment available that stops progression or improves vision in&#xD;
      patients with dry AMD or Stargardt disease.&#xD;
&#xD;
      Considering the success in animal studies and observational human studies with omega-3 fatty&#xD;
      acids supplementation when the blood ratio AA (arachidonic acid)/EPA (eicosapentaenoic acid)&#xD;
      is &lt;2, the sponsor hypothesizes that, when the blood ratio of AA/EPA is maintained below 2,&#xD;
      the visual acuity in the group with active supplements will improve, in comparison to the&#xD;
      control group, in patients with moderate and severe dry AMD and moderate and severe&#xD;
      Stargardt.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Actual">September 22, 2020</completion_date>
  <primary_completion_date type="Actual">September 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change of letters (BCVA) from screening to 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Mean change of letters (BCVA) from screening to 24 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Dry AMD</condition>
  <condition>Stargardt Disease 1</condition>
  <arm_group>
    <arm_group_label>Omega 3 fatty acids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omega 3 fatty acids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sunflower oil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Madeos</intervention_name>
    <description>Arm 1: Omega 3</description>
    <arm_group_label>Omega 3 fatty acids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Arm 2 : Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ages from 18 to 85 years old.&#xD;
&#xD;
          -  Group 1: For moderate dry macular degeneration the BCVA must be between 50 and 70&#xD;
             (ETDRS) at Screening Visit V1. There must be a large drusen &gt;125 µm within 1mm from&#xD;
             the centre of the fovea. Geographic atrophy can be present but must be &gt;300 µm away&#xD;
             from centre of fovea;&#xD;
&#xD;
          -  Group 2: For severe dry macular degeneration the BCVA must be between 41 and 49&#xD;
             (ETDRS) at Screening Visit V1. Geographic atrophy can involve the fovea but must be&#xD;
             &lt;2500 µm in diameter or any size GA but &gt;200 µm from centre of fovea anywhere;&#xD;
&#xD;
          -  Group 3: For moderate Stargardt disease the BCVA must be between 50 and 70 (ETDRS) at&#xD;
             Screening Visit V1. The geographic area must be &lt;2.0 mm in diameter anywhere;&#xD;
&#xD;
          -  Group 4: For severe Stargardt disease the BCVA must be between 41 and 49 (ETDRS) at&#xD;
             Screening Visit V1. The geographic area must be &lt;2.5 mm in diameter anywhere;&#xD;
&#xD;
          -  Willingness to take the randomised trial investigational product for 6 months;&#xD;
&#xD;
          -  Willingness to consent and undergo the examinations/blood testing at the visits;&#xD;
&#xD;
          -  Be able to swallow large soft gel capsules;&#xD;
&#xD;
          -  Take other supplements as usual; The EPA and DHA intake must be less than 1200 mg/day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any ocular disease in either eye including: Diabetic retinopathy, Central serous&#xD;
             retinopathy, Epiretinal membrane, Optic atrophy, Macular hole or pseudohole, Retinal&#xD;
             vein occlusion, Amblyopia;&#xD;
&#xD;
          -  Previous wet AMD in the study eye;&#xD;
&#xD;
          -  Any previous ocular surgery, which may influence progression of dry macular&#xD;
             degeneration e.g. trabeculectomy, previous refractive surgery, pterygium surgery.&#xD;
             Cataract surgery more than 6 months is not an exclusion criterion unless a&#xD;
             complication has occurred during surgery;&#xD;
&#xD;
          -  Any topical medication administered for other diseases such as glaucoma. Artificial&#xD;
             tears up to 3/day will be allowed;&#xD;
&#xD;
          -  Any ocular condition such as allergic conjunctivitis, moderate to severe dry eyes,&#xD;
             scleritis, uveitis, keratitis, ocular Herpes Simplex keratitis, ectropion, entropion,&#xD;
             ocular surface scaring;&#xD;
&#xD;
          -  Any systemic conditions such as gastrointestinal disease e.g. irritable bowel&#xD;
             syndrome, Crohn's disease, cancer, etc;&#xD;
&#xD;
          -  Any drugs which could affect the eye administered up to 6 months before screening&#xD;
             e.g.: Steroids, Ethambutol, Tamoxifen, Chloroquine, Hydroxychloroquine;&#xD;
&#xD;
          -  Any condition that would not allow follow up e.g. alcoholism or drug abuse;&#xD;
&#xD;
          -  Allergy to any ingredients of the active or placebo pills.&#xD;
&#xD;
          -  Pregnant or lactating;&#xD;
&#xD;
          -  Current use of EPA/DHA supplements in excess of 1200 mg/day;&#xD;
&#xD;
          -  History of liver disease;&#xD;
&#xD;
          -  Anti-coagulation therapy such as warfarin/heparin/aspirin/dabigatran/ clopidogrel etc;&#xD;
&#xD;
          -  Bleeding tendencies e.g. coagulopathies;&#xD;
&#xD;
          -  History of atrial fibrillation;&#xD;
&#xD;
          -  Inability to give informed consent (impaired mental capacity e.g. psychiatric&#xD;
             deficit);&#xD;
&#xD;
          -  Smokers or patients who have not been completely smoke free over the past 5 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, Justus-Liebig-University-Giessen</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi G. d'Annunzio Chieti-Pescara</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Santi Paolo e Carlo</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Ophthalmology, University Vita Salute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Omega-3</keyword>
  <keyword>dry AMD</keyword>
  <keyword>Stargardt</keyword>
  <keyword>visual acuity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Stargardt Disease</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

